Hypoparathyroidism clinical trials

Explore recruiting hypoparathyroidism clinical trials.

Recruiting hypoparathyroidism studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypoparathyroidism trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Treatment with Indapamide in Patients with Post-Surgical Hypoparathyroidism

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Impact of Intraoperative Arteriography with Indocyanine Green in Preserving the Parathyroid Glands During Total Thyroidectomy With or Without Central Cervical Lymph Node Dissection. A Multicenter Prospective Randomized Trial.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism

Denmark, Germany, Norway, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)

Italy, Netherlands, Denmark, Belgium, France, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Hypoparathyroidism trials by city

Hypoparathyroidism in Toronto Hypoparathyroidism in Vancouver Hypoparathyroidism in Montreal Hypoparathyroidism in Calgary Hypoparathyroidism in Edmonton Hypoparathyroidism in Ottawa Hypoparathyroidism in Winnipeg Hypoparathyroidism in Quebec City Hypoparathyroidism in Hamilton Hypoparathyroidism in Kitchener Hypoparathyroidism in London Hypoparathyroidism in Halifax Hypoparathyroidism in New York Hypoparathyroidism in Los Angeles Hypoparathyroidism in Chicago Hypoparathyroidism in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease